HCW Biologics (HCWB) Short Interest Ratio & Short Volume

Short interest is the volume of HCW Biologics shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 1,300 shares of HCWB short. 0.01% of HCW Biologics' shares are currently sold short. Learn More on HCW Biologics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.01% of HCW Biologics' floating shares are currently sold short.

HCW Biologics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,300 shares, a decline of 84.9% from the previous total of 8,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

HCW Biologics currently has issued a total of 37,820,000 shares. Some of HCW Biologics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. HCW Biologics currently has a public float of 17,850,000 shares.

0.01% of HCW Biologics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to HCW Biologics: T2 Biosystems, Inc. (22.49%), Enlivex Therapeutics Ltd. (1.10%), Alimera Sciences, Inc. (0.20%), Rigel Pharmaceuticals, Inc. (3.22%), Veru Inc. (8.65%), Sagimet Biosciences Inc. (10.29%), Context Therapeutics Inc. (1.38%), Cartesian Therapeutics, Inc. (13.69%), ProQR Therapeutics (0.45%), InterCure Ltd. (0.26%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling HCWB is an investing strategy that aims to generate trading profit from HCW Biologics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for HCW Biologics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of HCWB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HCWB, twice per month. The most recent reporting period available is May, 15 2024.